Introduction {#S1}
============

Pulmonary infection caused by non-tuberculous mycobacteria (NTM) is an emerging threat with serious public health consequences. Mortality rates of 10--40% due to lung disease caused by these lesser known "cousins" of *Mycobacterium tuberculosis* (TB) have been increasingly reported in the developed world ([@B1]--[@B4]). The prolonged treatment regimens lasting months to years and increasing antibiotic resistance to front-line antibiotics make these pathogens difficult and expensive infections to treat. Over 180 species of NTM are known to cause disease in humans of which the *Mycobacterium avium* complex (MAC) and the *Mycobacterium abscessus* complex (MABS) are of dominant clinical interest ([@B5]). These species account for over 80% of NTM disease worldwide and are among the most common causative agents for NTM lung disease ([@B6]). The global increase in disease prevalence over the past 10--15 years has led to an increased focus on patient-oriented research ([@B7], [@B8]).

The emergence and spread of human transmissible clones of MABS has been recently reported ([@B9]) and is the first evidence of person-to-person transmission of NTM that were, up until to now, considered environmentally acquired by susceptible individuals. MABS infection is associated with rapid decline in lung function and extensive lung damage which can be life threatening, particularly in patients already compromised with respiratory problems such as those with cystic fibrosis (CF). Multi-drug resistance (MDR) of these pathogens contributes to prolonged and difficult treatment regimens and high relapse rates, both of which lead to increased morbidity/mortality and escalating treatment costs in a group of patients who are already highly susceptible to opportunistic infections. The presence of MABS is an absolute contradiction to lung transplantation ([@B10]--[@B13]).

Non-tuberculous mycobacteria infections are also a growing health concern among the elderly population. Pre-existing lung diseases, such as chronic obstructive pulmonary disease and bronchiectasis are known risk factors for developing NTM infection as are lung malignancies, immune modulatory treatments, and HIV/AIDS ([@B7], [@B14]). The worldwide increase in NTM infections in apparently immunocompetent middle aged to elderly patients, in the setting of an aging population contributes to an increased population of susceptible individuals at-risk of developing NTM infection.

Delineating immune function in NTM infection is of fundamental interest in order to understand how and why these infections: (i) occur in specific at-risk populations; (ii) progress in some patients and; (iii) resolve in others. The importance of Th1-type cell-mediated immunity in anti-mycobacterial immunity is well established. Low production of the Th1 cytokines IFNγ and TNFα and more recently, low production of IL-17 and IL-10 have been associated with NTM infection ([@B15]--[@B21]).

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and T-cell immunoglobulin domain and mucin domain 3 (TIM-3) are negative regulatory check points that are important for T cell tolerance and regulation during the immune response. Widely known for their use as targets in cancer immunotherapy ([@B22]), these immune checkpoints have also been shown to play an important role in T cell exhaustion during chronic infections such as TB ([@B23]--[@B27]). The role of these molecules in NTM infection has yet to be explored. Information on T cell "quality" in terms of cytokine production is also lacking. Polyfunctional T cells are known to determine pathogenesis and disease progression of TB and other infectious and immune-related diseases ([@B26], [@B28]--[@B30]).

In order to discover new targets for therapeutic intervention and rational vaccine design, an improved understanding of the molecular and cellular host defense mechanisms that provide protective immunity toward NTM is required. The present study comprehensively characterized the immune profile of NTM patients by performing high-dimensional flow cytometry-based analysis in two cohorts of NTM patients. The first group was CF patients and the second group was immunocompetent middle aged to elderly patients with MABS infection. We show across both groups abnormalities in global T cell function that associate with individuals at risk of infection.

Patients and Methods {#S2}
====================

Patient Cohorts {#S2-1}
---------------

Two patient cohorts were studied. The CF patient cohort (*n* = 24) included three groups of patients; (i) CF patients with active pulmonary MABS infection (defined as MABS identified by at least one positive culture within a 12-month period) *n* = 6 (CF^Act^) and one with MAC infection; (ii) patients who had a previous diagnosis of MABS infection who had undergone treatment and were now in remission as defined by at least six clear sputum samples (smear and culture negative over a 1-year period; CF^Past^ *n* = 8) and; (iii) patients who were confirmed as having chronic *Pseudomonas aeruginosa* (Pa) infection by the Leeds criteria ([@B31]), but with no history of or current NTM infection were included as a "within-disease" control group (CF^Controls^ *n* = 9). Five of the six patients with active MABS infection had chronic Pa infection and one had intermittently positive sputum cultures (≤50% of serial sputum cultures positive) for Pa. Sex, age, and demographic-matched healthy controls were recruited from unrelated adult volunteers (HC^A^ *n* = 10). The second patient cohort was elderly patients diagnosed with active NTM (NTM^Act^ *n* = 10) all of whom had confirmed MABS infection. Healthy controls (HC^B^) sex, age, and demographic-matched to the NTM^Act^ patients were recruited from healthy adult volunteers (*n* = 10). All samples were obtained with written consent and all protocols were approved by the Human Research Ethics Committees of the QIMR Berghofer Medical Research Institute, The Prince Charles Hospital, and Greenslopes Private Hospital, Australia.

Blood Samples and Processing {#S2-2}
----------------------------

Peripheral blood mononuclear cells (PBMC) were separated from venous blood by Ficoll--Paque PLUS (GE Health) density gradient method and were cryopreserved in R10 medium (RPMI-1640 containing 10% fetal bovine serum (FBS) with 100 U/ml penicillin and 100 µg/ml streptomycin) supplemented with 10% DMSO (Sigma-Aldrich). Thawed cells were rested overnight in R10 medium at 37°C. Cells were then stained for viability, counted, and aliquoted into three 96-well plate. Cells in plate one were resuspended in staining buffer (PBS with 2% FBS) and stained for direct *ex vivo* flow cytometric analysis. Cells in plate two and three were split into two aliquots and one aliquot was activated with PMA ionomycin (PMA/I) (Ebioscience) at 1× final concentration in the presence of Brefeldin A 1 μg/ml (Ebioscience) and Monensin 0.1 μg/μl (Ebioscience) for 6 h at 37°C. The other aliquot was incubated in R10 without PMA/I as an *ex vivo* baseline control.

Flow Cytometric Analysis {#S2-3}
------------------------

The cells in plate one were stained for surface markers delineating major immune cell lineages and evaluated for TIM-3 expression. Panel one included surface markers αCD4-FITC (BD), αCD8-Percp-Cy5.5 (Biolegend), αCD16-PECY7 (BD), αCD19-BV421 (BD), αCD14-APC (BD), and αTIM-3-PE (R&D Systems). Cells in plate two were stained with panel 2 which included surface markers αCD4-FITC (BD), αCD8-Percp Cy5.5 (Biolegend), activation marker αCD25-PE (BD), and exhaustion marker αPD-1-BV605 (BD). Staining for intracellular exhaustion marker αCLTA-4-BV421 (BD) and nuclear transcription factor αFOXP3-APC was performed after fixation and permeabilization on ice with FOXP3 Permeabilization kit (Ebioscience) according to manufacturers' instructions. Plate three cells were activated with PMA/I and incubated with αCD107a-FITC (BD) during activation. Cells were then washed and resuspended in staining buffer and surface staining was performed with panel 3; αCD3-PECY7 (BD), αCD4-BV711 (BD), and αCD8-Percp-Cy5.5 (BD) markers. Intracellular cytokines were stained with αINFγ-AlexaFlour700 (BD), αTNFα-APC (BD), and αIL-2-PE (BD) after fixation and permeabilization with Fix/Perm buffer kit (BD) for intracellular staining. Stained samples were run on a BD LSR Fortessa 4 laser cytometer (BD). Sample acquisition was performed on BD FACSDiva 8.0 (BD) and data were analyzed with FlowJo v10 (TreeStar) and Cytobank[^1^](#fn1){ref-type="fn"} for viSNE analysis ([@B32]).

Statistical Analysis {#S2-4}
--------------------

Statistical analysis was performed with SPSS 22, Graphpad PRISM (v6.05), and Gmine[^2^](#fn2){ref-type="fn"} ([@B33]). Comparison of means over multiple groups was performed using one-way ANOVA tests with Tukeys *post-hoc* comparisons, while comparisons between two groups were performed using unpaired *t*-tests or Wilcoxon rank test. Hierarchical clustering and biomarker identification was performed in Gmine. Stepwise regression was performed to identify variables associated with NTM disease. The patient in CF^Act^ group with active MAC infection was excluded from these analyses. However, the patients' data point was included in scatter plots as a blue circle to visually demonstrate how active MAC infection compares to active MABS infection. Polyfunctionality analysis was performed using Pestle and SPICE V5[^3^](#fn3){ref-type="fn"} ([@B34]).

Results {#S3}
=======

Distinct T Cell Phenotype in CF Patients Susceptible to MABS Infection {#S3-1}
----------------------------------------------------------------------

We first investigated the phenotypic and functional immune profiles of PBMCs in CF patients to probe for functional deficiencies that could underlie predisposition to NTM infection. Cohorts were categorized as CF with active NTM infection (CF^Act^), CF with a past history of NTM infection (CF^Past^), CF with chronic Pa infection (and no history of NTM infection CF^Control^) and healthy controls (HC^A^), all matched in both age (ANOVA *P* = 0.350) and gender distribution (Chi-square *P* = 0.445). Demographic and clinical characteristics of patient groups are shown in Table [1](#T1){ref-type="table"}. All patients had either active or past MABS infection with the exception of one patient who had active MAC infection.

###### 

Table shows demographic of cystic fibrosis (CF) cohorts and elderly patient group.

                                                                   CF^Act^                                             CF^Past^      CF^Controls^   NTM^Act^
  ---------------------------------------------------------------- --------------------------------------------------- ------------- -------------- ------------------------------------
  Mean age (SD)                                                    32.6 (13.6)                                         34.9 (10.4)   33.1 (8.0)     75.6 (9.23)
  Male:female                                                      06:01                                               06:02         06:03          03:07
  Non-tuberculous mycobacteria (NTM) infection at time of sample   MABS (6) MAC (1)[^a^](#tfn1){ref-type="table-fn"}   None          None           MABS (10)
  **History of NTM infection**                                                                                                                      
  MABS                                                             0                                                   8             0              0
  MAC                                                              3[^b^](#tfn2){ref-type="table-fn"}                  0             0              3[^c^](#tfn3){ref-type="table-fn"}
  **Other infections**                                                                                                                              
  *Pseudomonas aeruginosa*                                         5                                                   8             9              4
  *Aspergillus* spp                                                0                                                   0             0              1
  *Burkholderia* spp[^d^](#tfn4){ref-type="table-fn"}              0                                                   1             1              0
  **Lung function**                                                                                                                                 
  \>70% FEV1                                                       4                                                   1             3              8
  30--70% FEV1                                                     3                                                   6             5              2
  \<30% FEV1                                                       0                                                   1             1              0
  **Radiographic features**                                                                                                                         
  Bronchiectasis                                                   7                                                   8             9              10

*CF^Act^-CF patients with active NTM infection. CF^Past^-CF patients with past NTM infection. Both groups of patients had a history of P. aeruginosa infection. CF^Controls^-control CF patients with chronic P. aeruginosa infection. NTM^Act^-elderly patients with active NTM infection. N/A, not applicable; MABS, Mycobacterium abscessus complex; MAC, Mycobacterium avium complex*.

*^a^One patient in CF^Act^ group had active MAC infection. This patient was excluded from ANOVA and biomarker analysis but included in general profiling analysis. Data point is shown as a blue circle in scatter plots for ANOVA analysis in Figures [1](#F1){ref-type="fig"}A and [2](#F2){ref-type="fig"}A*.

*^b^One patient in CF^Act^ group had prior history of MAC infection while two subsequently developed MAC infection*.

*^c^In NTM^Act^ elderly patient group, one patient had a history of MAC infection prior to MABS infection while two others developed MAC infection after treatment of current episode of MABS infection*.

*^d^Burkholderia cepecia complex*.

Flow cytometric analysis of PBMCs revealed no significant differences in the percentage of B cells (CD19^+^), total CD4^+^ T cells (CD3^+^CD4^+^), total CD8^+^ T cells (CD3^+^CD8^+^), or in TIM-3 expression levels on cell subsets between the CF patients and healthy controls (data not shown). Comparison of Tregs (CD4^+^ CD25^+^ FOXP3^+^) between cohorts showed higher percentages in CF^Act^ and CF^Past^ groups compared to the CF^Control^ group (Figure [1](#F1){ref-type="fig"}A). Analysis of the individual expression of activation marker CD25 and exhaustion marker CTLA-4 on CD4^+^ T cells revealed significantly higher expression of CD25 and CTLA-4 in CF^Act^ group compared to the CF^Control^ group (Figure [1](#F1){ref-type="fig"}A). Higher co-expression of CD25 and CTLA-4 was seen on CD4^+^ T cells in CF^Act^ group compared to the CF^Control^ group and higher percentages of CD25 and CTLA-4 double-negative CD4^+^ T cells were observed in the CF^Control^ group and HC^A^ group (Figure [1](#F1){ref-type="fig"}A).

![Divergent T cell activation and exhaustion profiles in cystic fibrosis (CF) patients based on non-tuberculous mycobacteria (NTM) infection status. **(A)** Flow cytometric analysis of *ex vivo* CD4^+^ T cells show significant differences in Treg percentages and marker expression between patient groups. Significantly more Tregs were seen in both CF^Act^ and CF^Past^ groups compared to CF^Contro1^ (one-way ANOVA with *post-hoc* testing *P* = 0.013 and *P* = 0.042, respectively). Significantly higher CD25^+^ CD4^+^ T cells were observed in both CF^Act^ and CF^Past^ groups compared to CF^Contro1^ group (*P* = 0.0056 and *P* = 0.037, respectively). CD25 cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) double-positive T cells were significantly higher in CF^Act^ than in CF^Control^ (*P* = 0.019). A reciprocal reduction in CD25 CTLA-4 double-negative CD4^+^ T cells were seen in CF^Act^, CF^Past^, and HC^A^ groups compared to CF^Control^ (*P* = 0.001, *P* = 0.027, and *P* = 0.008, respectively). CF^Act^ patient with active *Mycobacterium avium* complex (MAC) infection is shown as a blue circle in scatter plots. This data point was not included in the ANOVA analysis but is shown here to demonstrate activation and exhaustion profile of a patient with an active NTM infection that is not MABS **(B)** Immune marker profiling of CD4^+^ T cells by SPICE showed differences in *ex vivo* phenotype in the CF^Contro1^ group compared to CF^Act^ (*P* = 0.0002), CF^Past^ (*P* = 0.0002), and HC^A^ (*P* = 0.005). PMA/I stimulation resulted in minor changes in maker profile with the CF^Control^ profile still being significantly different to CF^Act^ (*P* = 0.025) and CF^Past^(*P* \> = 0.018) though the difference with HC^A^was reduced (*P* = 0.057). **(C)** SPICE dot plots show expression levels of all combinations of markers CD25, CTLA-4, and programmed cell death protein 1 in CD4^+^ T cells both *ex vivo* and after PMA/I stimulation in CF patient and control groups. Groups with significantly different expression compared to HC^A^ (Wilcoxon rank test *P* \< 0.05) are indicated with \# symbol. Symbol color indicates significantly different group.](fimmu-09-01319-g001){#F1}

We next compared the overall pattern of immune marker expression of the CD4^+^ and CD8^+^ T cell compartments in terms of surface "phenotypic fingerprint." Analysis of triple, double, single, or nil expression of markers CD25, CTLA-4, and PD-1 on CD4^+^ T cells revealed a common fingerprint in CF^Act^ and CF^Past^ groups which was distinct from the CF^Control^ group (Figures [1](#F1){ref-type="fig"}B,C). A higher number of CLTA-4 single-positive cells were seen in patients with either active or past NTM infection as compared with the healthy control subjects (Figures [1](#F1){ref-type="fig"}B,C). The T cell fingerprint following PMA/I activation was not significantly different to *ex vivo* T cells (Figures [1](#F1){ref-type="fig"}B,C). The T cell fingerprint on CD8^+^ T cells was similar between different groups (Figure S1A in Supplementary Material) with significance found in CD8^+^ CD25 single positive T cells *ex vivo* in the CF^Act^ group and in the PMA/I-activated CF^Past^ group (Figure S1A in Supplementary Material). These data reveal a difference in systemic T cell phenotypes in CF patients with active or past NTM disease, particularly in CD4^+^ T cells, compared to CF patients with more common chronic Pa infection. There was no difference between CF patients with active or past NTM disease and healthy controls in terms of T cell fingerprint.

Distinct T Cell Function in CF Patients Susceptible to MABS Infection {#S3-2}
---------------------------------------------------------------------

Given the differences in surface T cell phenotypes between cohorts we next analyzed cytokine production post-mitogen stimulation. T cell cytokine production after PMA/I stimulation revealed a specific signature associated with NTM disease. TNFα-producing CD4^+^ T cells were significantly lower in both CF^Act^ and CF^Past^ groups compared to the CF^Control^ group (Figure [2](#F2){ref-type="fig"}A). TNFα production in CD4^+^ T cells was also markedly lower in both CF^Act^ and CF^Past^ compared to HC^A^ group, though this difference did not reach statistical significance (Bonferroni *post-hoc* test). IFNγ^+^ CD4^+^ T cells in the CF^Act^ group were higher than the CF^Control^ group (Figure [2](#F2){ref-type="fig"}A). In the CD8^+^ subset, IFNγ^+^ T cells from the CF^Act^ and CF^Past^ groups were higher than the CF^Control^ group (Figure [2](#F2){ref-type="fig"}A).

![Divergent T cell cytokine profiles in cystic fibrosis (CF) patients based on non-tuberculous mycobacteria (NTM) infection status. **(A)** Flow cytometric analysis of *ex vivo* activated CD4^+^ T cells show significantly lower IFNγ^−^ TNFα^+^ (*P* = 0.026 and *P* = 0.030) and CD107a^−^ TNFα^+^ (*P* = 0.026 and *P* = 0.027) T cells in CF^Act^ and CF^Past^ groups, respectively compared to the CF^Contro1^ group. Differences were not significant when comparing the HC^A^ group with ANOVA *post-hoc* testing. A similar pattern of increased TNFγ^+^ CD4^+^ T cells was seen in the HC^A^ group. Significantly more IFNγ^+^ TNFα^−^ CD4^+^ T cells were seen in CF^Act^ patients compared to CF^Contro1^ patients (*P* = 0.0315) and significantly more IFNγ^+^ TNFα^−^ CD8^+^ T cells were seen in both CF^Act^ and CF^Past^ groups (*P* = 0.014 and *P* = 0.0047, respectively) compared to CF^Contro1^ group. CF^Past^ had significantly more IFNγ^+^ TNFα^−^ CD8^+^ T cells compared to HC^A^(*P* = 0.005). CF^Act^ patient with active *Mycobacterium avium* complex infection is shown as a blue circle in scatter plots. This data point was not included in the ANOVA analysis but is shown here to demonstrate cytokine profile of a patient with an active NTM infection that is not MABS **(B)** Polyfunctionality profiling of CD4^+^ T cells by SPICE showed differences in *ex vivo* functions in CF^Act^ and CF^Past^ groups compared to CF^Control^ (*P* = 0.056 and *P* = 0.041, respectively) and HC^A^ groups (*P* = 0.022 and *P* = 0.012, respectively). TNFα mono-expressing CD4^+^ T cells (blue arc) were significantly lower in the two NTM patient groups compared to the CF^Contro1^ and HC^A^ groups. **(C)** SPICE dot plots show polyfunctionality profile of all combinations of cytokine expression in CD4^+^ T cells after PMA/I stimulation. Groups with significantly different expression compared to CF^Contro1^ (Wilcoxon rank test *P* \< 0.05) are indicated with \# symbol. Symbol color indicates significantly different group.](fimmu-09-01319-g002){#F2}

Polyfunctionality in CD4^+^ and CD8^+^ T cells was next examined. As CD107a represents degranulation and cytolytic activity, the expression of this marker was included in the polyfunctionality profile in addition to TNFα, IFNγ, and IL-2. Both CF^Act^ and CF^Past^ groups showed a unique polyfunctionality profile compared to both CF^Controls^ and HC^A^ groups (Figure [2](#F2){ref-type="fig"}B). Both CD4^+^ TNFα-producing single positive T cells (mono-functional) and CD4^+^ TNFα^+^ IL2^+^ double-positive cells (dual-functional) were seen to be significantly reduced in both CF^Act^ and CF^Past^ groups compared to both control groups (Figures [2](#F2){ref-type="fig"}B,C). Significantly higher IFNγ mono-functional T cells were seen in the CF^Past^ group compared to the CF^Control^ group though there was no difference compared to the HC^A^ group. There was also no difference in the number of triple- and quadruple-functional T cells between groups. When CD8^+^ T cell polyfunctionality was compared, significantly higher numbers of IFNγ producing mono-functional cells were seen in both CF^Act^ and CF^Past^ groups compared to both control groups though there was no significant difference in terms of overall polyfunctionality profile (Figure S2 in Supplementary Material). Total TNFα-producing CD8^+^ T cells were significantly higher in the HC^A^ and CF^Control^ groups compared to CF^Act^ and CF^Past^ groups.

Hierarchical clustering analysis of cytokine production and CD107a expression data showed a grouping of CF^Act^ and CF^Past^ groups, while the CF^Control^ and HC^A^ groups clustered together (Figure [3](#F3){ref-type="fig"}A). Based on global cytokine and CD107a expression profiles, patients with NTM disease (either past or present) could be grouped together. There was no clear separation of the active and past NTM infection groups indicating that based on all clustering variables; no global differences were seen between these two groups. The same pattern was observed in the chronic Pa infection group CF^Control^ and the HC^A^ group where both groups clustered together.

![Multivariate T cell analysis of mitogen-stimulated cytokine secretion profiles. **(A)** Unsupervised hierarchical clustering of mitogen-stimulated CD4^+^ and CD8^+^ T cell cytokine secretion profile show divergence based on non-tuberculous mycobacteria infection status. Each column represents an individual (patient/control) and each row represents a clustering variable (cytokine secretion pattern). Clustering patterns shown according to primary group \[patient with cystic fibrosis (CF) black, or healthy control gray\] and secondary group (CF^Act^-light green, CF^Past^-dark green, CF^Contro1^-white, and HC^A^-black). Clustering of CF^Ac^ and CF^Past^ patients with one exception and clustering of CF^Contro1^ and HC^A^ with one exception. **(B)** Principle component analysis (PCA) and canonical co-variate analysis (CCA) show significant clustering (*P* = 0.02) of subjects by patient group. Marked overlap between CF^Act^ and CF^Past^ groups is seen in terms of global cytokine secretion profile indicating an overall similarity in secretion profile. CF^Contro1^ group diverges further from CF^Act^ and CF^Past^ groups.](fimmu-09-01319-g003){#F3}

Given this common hierarchical clustering result between CF^Act^ and CF^Past^ cohorts, we next redefined the cohorts for subsequent data analysis. Patients who had either active or past NTM infection (CF^Act^ and CF^Past^) were defined as the "NTM disease" cohort and CF patients with chronic Pa infection and healthy controls (CF^Control^ and HC^A^) were defined as the "control" cohort (i.e., persons with no history of NTM infection). These two variables were then used as outcomes to analyze data for predictive biomarkers using GMine multivariate analysis software ([@B33]). CCA analysis showed significant clustering between these groups (Figure [3](#F3){ref-type="fig"}B). Biomarker analysis identified 13 significant predictors of "NTM disease" after correction for multiple comparisons (FDR) (Figure [4](#F4){ref-type="fig"}A). Unsurprisingly, significant predictors included combinations of TNFα and IFNγ production. The stepwise regression model (area under the curve, AUC 100%) identified percentage CD8^+^ IL2^+^ TNFα^−^ T cells and percentage CD8^+^ IFNγ^+^ TNFα^−^ T cells as the best predictors of NTM disease (Figure [4](#F4){ref-type="fig"}B).

![Top immune biomarker candidates for diagnosis of non-tuberculous mycobacteria (NTM) infection status in cystic fibrosis cohorts. **(A)** Flow cytometric biomarkers for NTM disease state from cytokine secretion profile data (Wilcoxon rank test). Graph shows log odds ratio for each biomarker candidate for diagnosis of NTM disease state (negative versus exposed state) with 95% CI. (P, probability; FDR, false discover rate; AUC, area under the curve). **(B)** Stepwise regression model (forward selection) for NTM infection status. Fitted model contains 18 variables shown in table with a final AIC of −30 and an AUC 1. Plots show contribution of each variable to model and fitted value for each patient/control (green dots) when model is applied showing an AUC = 1.](fimmu-09-01319-g004){#F4}

Distinct T Cell Function in Elderly Patients With Active MABS Infection {#S3-3}
-----------------------------------------------------------------------

To determine whether this immune profile would also be found in other independent disease cohorts, we next investigated elderly patients with active NTM infection (NTM^Act^). In Australia, the rate of notified NTM cases per 100,000 population has increased by approximately 17% per year between 2012 and 2015 ([@B35]). The reasons for this increase are unknown, and there is yet no predictor to identify at-risk individuals. To determine if underlying immune dysfunction may be a predictive factor for NTM infection we compared NTM^Act^ patients with elderly healthy controls (HC^B^). We found that Tregs were increased in the peripheral blood of elderly NTM^Act^ patients compared to elderly HC^B^ (Figure [5](#F5){ref-type="fig"}A). Elevated CD25 and CTLA-4 expression was also seen on CD4^+^ T cells in the NTM^Act^ group alongside increased PD-1 expression on CD4^+^ CD25^+^ T cells. Analysis of the phenotypic fingerprint of CD25, CTLA-4, and PD-1 expression in CD4^+^ T cells showed a specific signature in NTM^Act^ patients with elevated CD25 and CTLA-4 double-positive T cells as well as elevated CD25 single-positive T cells in the NTM^Act^ group (Figures [5](#F5){ref-type="fig"}A,B). T cells negative for all three markers (triple-negative) were significantly higher in the HC^B^ group compared to NTM^Act^ patients. Four significant phenotypic differences *ex vivo* and during mitogen stimulation were observed between the NTM^Act^ group and HC^B^ group (Figure [5](#F5){ref-type="fig"}C). *Ex vivo* CD8^+^ T cell fingerprint was identical between HC^B^ and NTM^Act^ cohorts (data not shown).

![Evidence of CD4^+^ T cell activation and exhaustion in immunocompetent individuals with active non-tuberculous mycobacteria (NTM) infection. **(A)** Flow cytometric analysis of *ex vivo* CD4^+^ T cells showed significantly more Tregs in NTM^Act^ group compared to HC^B^ group (*P* = 0.028). Significantly more CD25^+^ CTLA4^+^ and CD25^+^ CTLA4^−^ CD4^+^ T cells were seen in NTM^Act^ group (*P* = 0.002 and *P* = 0.009, respectively) compared to HC^B^. A reciprocal increase in CD25^−^ CTLA4^−^ CD4^+^ T cells was seen in the HC^B^ group (*P* = 0.001) compared to disease group. Higher numbers of PD1^+^ CD4^+^ T cells (*P* = 0.021) and CD25^+^ PD1^+^ CD4^+^ T cells (*P* = 0.011) were seen in the NTM^Act^ group. CD25^+^ PD1^−^ T cells were significantly higher in NTM^Act^ group (*P* \< 0.001) and CD25^−^ and PD1^−^ CD4^+^ T cells were significantly higher in HC^B^ group (*P* \< 0.001). **(B)** Phenotyping and polyfunctionality profiling of CD4^+^ T cells by SPICE showed differences in NTM^Act^ and HC^B^ groups directly *ex vivo* and post PMA/I stimulation. Phenotype profiles were significantly different between groups both *ex vivo* (*P* = 0.0013) and post stimulation (*P* = 0.022). Significantly more CD25^+^ CTLA4^+^ T cells were observed in NTM^Act^ groups compared to HC^B^. **(C)** SPICE dot plots show phenotype profile of all combinations of markers CD25, CTLA4, and PD1 in CD4^+^ T cells both *ex vivo* and post PMA/I stimulation between NTM^Act^ and HC^B^ groups. Significantly different expression compared to HC^B^ (Wilcoxon rank test *P* \< 0.05) is indicated with \# symbol.](fimmu-09-01319-g005){#F5}

Mitogen stimulation and polyfunctionality analysis in the elderly cohorts revealed a very different profile to that seen in CF patients. In the NTM^Act^ group, significantly higher TNFα production by CD8^+^ T cells was observed (Figure [6](#F6){ref-type="fig"}A), while there was no difference in the number of TNFα-producing CD4^+^ T cells between groups (Figure S3A in Supplementary Material). IFNγ single-positive CD8^+^ T cells were similar in patients and controls (Figures [6](#F6){ref-type="fig"}B,C) as was the overall polyfunctionality profile in CD4^+^ T cells (Figures S3A,B in Supplementary Material).

![Divergence of CD8^+^ T cell cytokine profiles in immunocompetent individuals with active non-tuberculous mycobacteria (NTM) infection. **(A)** Flow cytometric analysis of *ex vivo* CD8^+^ T cells showed significantly more IFNγ^−^ TNFα^+^ cells (*P* = 0.01) and IL2^−^ TNFα^+^ cells (*P* = 0.048) in NTM^Act^ compared to HC^B^. **(B)** Polyfunctionality profiling of CD8^+^ T cells shown in pie charts were not significantly different between the two groups. However, significantly higher TNFα mono-functional CD8^+^ T cells were observed in NTM patient group (*P* = 0.002). **(C)** SPICE dot plots show polyfunctionality profile of all combinations of cytokine expression in CD8^+^ T cells after PMA/I stimulation between NTM^Act^ and HC^B^ groups. Significantly different expression compared to HC^B^ (Wilcoxon rank test *P* \< 0.05) is indicated with \# symbol.](fimmu-09-01319-g006){#F6}

Discussion {#S4}
==========

The increased incidence and prevalence of NTM disease in recent years, warrants a more comprehensive understanding of immunity in susceptible individuals ([@B7]). Due to increasing antibiotic resistance of NTM strains and poor patient-outcomes in particular MABS, immunomodulatory strategies may emerge as important adjuvants to conventional anti-mycobacterial therapy in NTM disease. Here, we dissect faults in immunity in two cohorts of patients (CF and elderly) with NTM lung infection and matched controls to identify the underlying blood immune signatures of each disease. Blood was examined given: (i) T cells are known to traffic between the blood and lung ([@B36]); (ii) NTM-specific T cells have been observed in the blood ([@B37]); and (iii) blood is easy to access for diagnostic tests. The first cohort included CF patients with active NTM disease, CF patients with past NTM disease who had been successfully treated and were now in disease remission, CF patients with chronic Pa infection who had no history of NTM infection and a group of matched healthy controls. The second cohort included elderly patients with NTM infection and matched healthy controls. All control individuals in both cohorts had active or past MABS infection with the exception of one patient who had MAC infection.

The frequency of Tregs was significantly increased in CF patients with active and past NTM infection compared to CF patients with chronic Pa infection. These data contrast with the elderly cohort, where Tregs significantly were higher in elderly NTM patients compared to healthy controls. This was similarly observed by Hector et al., where lower number of Tregs was found in both the airways and peripheral blood of CF patients compared to healthy controls and a further reduction in Tregs was seen in patients with chronic Pa infection ([@B38]). The lack of difference in Treg percentages between CF NTM patients and healthy controls could be an indication of an increase in Tregs following NTM infection. This rationale would align with our findings of elevated Tregs in the elderly immunocompetent patients with active NTM infection. Of note, increased Treg numbers have been observed in the peripheral blood of TB patients ([@B39]--[@B41]) indicating overlap between TB and NTM immunopathology.

When examining the T cell fingerprint, CF patients with active and past MABS infection were different to control patients with chronic Pa infection, though they were similar to the healthy control group. This finding suggests differences in T cell immunity between CF patients susceptible to MABS and CF patients who have no history of NTM infection.

Distinct activation and exhaustion profiles were seen in both patient cohorts with NTM infection compared to corresponding controls. Higher numbers of CD4^+^ T cells co-expressing the activation marker CD25 and the exhaustion marker CTLA-4 were seen in CF patients with both active and past NTM infection. In the elderly cohort, a similar pattern of increased CD25 and CTLA-4 co-expression was observed on CD4^+^ T cells. PD-1 expression was also increased on CD4^+^ T cells, suggesting an exhausted immune phenotype. High PD-1 expression on T cells associates with increased TB disease burden ([@B26]). Increased PD-1 expression on T cells, B cells, NK cells, and monocytes has also been reported in patients with MAC infection ([@B42]). In mice, PD-1 gene knockout can enhance TB resistance by preventing over-production of IFNγ ([@B43]). However, another study showed that PD-1 gene knockout mice can be more susceptible to NTM infection ([@B44]). To date, the immune checkpoint CTLA-4 has not been studied in the context of NTM. Our data present the first finding of elevated CTLA-4 on T cells in NTM infection. The significance of this as well as elevated PD-1 expression on T cells indicates a degree of immune suppression in NTM infection. No PD-1 (or CTLA-4) antibody blockade therapy has been examined *in vivo* on TB or NTM. Future research should focus on the prospect of treating NTM patients using PD-1 and/or CTLA-4 antibody blockade.

TNFα directly activates macrophages to restrict mycobacterial growth and induces apoptosis of infected macrophages leading to bacterial killing ([@B45]--[@B47]). TNFα is also essential for granuloma formation and disease restriction during mycobacterial pathogenesis highlighting its importance for *in vivo* control of the pathogen ([@B48]). Animals deficient in TNFα are highly susceptible to disseminated forms of TB ([@B49]). The cytokine polyfunctionality profiles seen in CF cohorts revealed underlying global TNFα deficiencies that could explain susceptibility to NTM infection in CF patients. Low TNFα secretion (mono-functional TNFα-secreting CD4^+^ T cells) was seen in CF patients with both active and past NTM infection, while increased TNFα secreting mono-functional CD8^+^ T cells were seen in elderly patients with NTM infection. Given that CF patients with both active and past infection exhibit this TNFα deficiency in response to mitogen, it is more likely that this phenotype is an underlying predisposition to disease rather than a direct effect of the disease. The contrasting pattern of TNFα secretion in the two disease scenarios is significant in the larger context of mycobacterial pathobiology. Studies of NTM immunity are conflicting and show both low and high levels of TNFα production ([@B12], [@B42], [@B50]--[@B52]), however, these studies did not perform in depth mapping of cell subsets. TNFα production has an important role in host resistance as treatment with anti-TNFα therapies are associated with increased susceptibility to active TB and reactivation of latent TB infection ([@B53]) and is correlated with NTM activation in autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, and psoriasis ([@B54]). Here, we have shown that the TNFα profiles can vary with disease setting. Thus, taking into account the individual patient profile is critical when interpreting these findings. Moreover, we have also shown that TNFα secretion levels vary according to cell subset and it may be specific deficiencies in certain cell subsets that predispose to disease. It is possible that low dose TNFα replacement therapy, *via* aerosol, for example, may aid standard of care in NTM treatment in CF. Indeed, other cytokine replacement therapies, such as IFNγ, IFNα, IL-2, GM-CSF, and IL-12 have shown promise against TB, MDR-TB, MAC, and MABS \[reviewed in Ref. ([@B53])\]. Systemically administered IFNγ has shown the most promise for clinical use ([@B55]).

The importance of IFNγ in anti-mycobacterial immunity is widely accepted and extensively studied in TB ([@B56]). Reduced IFNγ production in NTM infection has been shown in several studies ([@B51], [@B57], [@B58]) though contradictory results have also been reported ([@B16]). Akin to TNFα, we show that IFNγ secretion varies with cell subset and disease scenario. In the CF NTM cohort, increased IFNγ secretion was seen in both CD4^+^ and CD8^+^ T cells compared to healthy controls, whereas in the elderly NTM cohort, there was no significant increase in IFNγ-secreting cells in both CD4^+^ or CD8^+^ T cells. This could indicate an inadequate protective response rather than a deficiency of cytokine. Comparison of MABS infection in these two disease cohorts once again highlights the importance of the clinical context when searching for risk factors. However, one limitation of the study is the profiling of circulating lymphocytes which may differ to those at the site of disease.

The search for environmental and behavioral risk factors for NTM infection in CF patients has found increased acquisition in the tropics and decreased acquisition with macrolide treatment ([@B59]). Here, we show that it is also possible to define immune parameters in the circulatory blood that help to identify at-risk individuals. Specifically, we showed that CF patients can stratify CF into two groups based on Treg frequencies, CD4^+^ T cell surface phenotype (CD25 and CTLA-4) and cytokine production by CD4^+^/CD8^+^ T cells (IFNγ, TNFα, CD107a, and IL-2), with at-risk patients exhibiting a distinct deficiency in TNFα. We suggest that this immune signature could be further refined and validated in independent cohort studies, and then ultimately developed for use as a diagnostic tool to identify individuals who are at high risk of developing NTM infection. Targeted behavioral interventions for at-risk patients may subsequently decrease the risk of NTM acquisition from the environment or infected patients.

The role of CD8^+^ T cells in NTM infection in humans remains unclear. Research in TB in primate and mouse models has shown that CD8^+^ T cells are important in controlling experimental infection. However, the precise mechanism by which they contribute to protection is unknown ([@B60]). Regulatory CD8^+^ T cells have been identified in human TB, though their role in protection is also not clear ([@B60]).

This study specifically focused on MABS infection. It is important to highlight that the CF patient with active MAC infection (shown as a blue circle in Figures [1](#F1){ref-type="fig"}A and [2](#F2){ref-type="fig"}A) exhibited a T cell fingerprint and T cell functional profile very similar to patients with MABS infection (note; this patient was not included in statistical analysis). Additionally, it is also important to note the 2 of 6 CF MABS patients and 3 of 10 elderly MABS patients either had a previous history of MAC infection or subsequently developed MAC infection. This tentatively suggests that the susceptibility to NTM infection may occur through a common immune dysfunction pathway, although further antigen-specific immune studies are required to validate this hypothesis. If NTM-specific immune dysfunction is common in the individuals, targeted immunotherapies may help in correcting this deficit.

Limitations of this study include the small sample size due to restrictions in patient recruitment within a confined study duration. An additional, larger patient cohort will be essential to validate our predictive model. Limitations in sample volumes also restricted the analysis to *ex vivo* phenotyping and mitogen-activation signatures. Thus, antigen-specific immune responses were not conducted in this study. However, further research is warranted given the identification of significant global immune anomalies in this exploratory study. Anomalies in mitogen-triggered activation signatures in the global T cell compartment suggest an underlying immune deficiency in the patients that would likely translate to NTM-specific responses as seen in TB ([@B61], [@B62]).

In summary, our study presents the first data on immune checkpoint expression on T cell subsets in human MABS infection as well as the first comparison of T cell polyfuntionality between CF and non-CF patient groups with MABS infection in response to mitogen stimulation. We show that MABS infection in two different patient groups' exhibit specific immune phenotypes and show dysregulation in type 1 cytokine production and a global decrease in T cell "quality." In CF patients, TNFα-mediated immunity may hold the key to understanding the increased risk of MABS infection and guide future therapeutic interventions. In elderly individuals, interference with checkpoint molecules (PD-1 and CTLA-4) may guide future therapeutic interventions. Collectively, the study has revealed many potential associations between T cell phenotype and individuals at risk of MABS infection. The idea of an underlying immune dysfunction which predisposes certain individuals to NTM infection is attractive but very speculative. Larger populations and further functional experiments will be required to validate this hypothesis.
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